HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Core Insights - HOOKIPA Pharma Inc. announced updated Phase 2 data for eseba-vec in combination with pembrolizumab for treating HPV16+ relapsed or metastatic head and neck squamous cell carcinoma at SITC2024 [1][2] Group 1: Clinical Data - The study showed an overall response rate (ORR) of 52% and a disease control rate (DCR) of 80% among patients with PD-L1 CPS >20 [2] - Preliminary median progression-free survival (PFS) is greater than 16 months, with a 12-month overall survival (OS) rate of 83% [2] - 66.7% of confirmed responders are ongoing, and the clinical activity is supported by a robust T-cell response [2] Group 2: Safety Profile - The treatment exhibited manageable toxicity with a low level of serious treatment-related adverse events at 7.6% [2] - The safety profile allows most patients to maintain treatment [4] Group 3: Product Information - Eseba-vec (HB-200) is an investigational immunotherapeutic agent for HPV16+ cancers, specifically targeting recurrent/metastatic oropharyngeal squamous cell carcinoma [5] - It has received Fast Track Designation from the FDA and PRIME designation from the EMA for first-line treatment [5] Group 4: Company Overview - HOOKIPA Pharma focuses on developing next-generation immunotherapeutics using its proprietary arenavirus platform [6] - The company's pipeline includes therapies targeting HPV16+ cancers and partnerships for developing treatments for hepatitis B and HIV-1 [6]